NCT06222944

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

A Multi-Center, Multi-Cohort Study of the Efficacy and Safety of Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-regimen-failed Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess the efficacy and safety of a combination therapy consisting of Anlotinib, TQB2450 (a PD-L1 inhibitor), and Albumin-bound Paclitaxel regimens in patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who have failed the previous treatment with Claudin18.2 (CLDN18.2)-related regimens.

Conditions

• Gastric Cancer
• Adenocarcinoma of Esophagogastric Junction

Interventions

Type	Name	Description
DRUG	Anlotinib	Anlotinib: 12mg PO, QD, D1-14, Q3W;
DRUG	TQB2450	TQB2450: 1200 mg, IV, D1, Q3W
DRUG	Albumin-Bound Paclitaxel	125mg/m2 IV D1,8，Q3W

Timeline

• Start date: 2024-02-25
• Primary completion: 2025-08-25
• Completion: 2026-08-25
• First posted: 2024-01-25
• Last updated: 2024-01-25

Locations

1 site across 1 country: China